ArticleEye and vision (London, England)2026
Development of a predictive model based on aqueous cytokines data for response to anti-VEGF therapy in diabetic macular edema.
Article in Eye and vision (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundIntravitreal anti-vascular endothelial growth factor (VEGF) agents improve visual acuity in diabetic macular edema (DME). However, resistance, non-response, or recurrence occurs in many patients. Predictive biomarkers for anti-VEGF response are lacking. We aim to identify cytokine markers predictive of anti-VEGF response and elucidate cytokines involved in poor-response DME pathogenesis.
methodsA luminex assay was carried out to measure the concentration of cytokines in the aqueous humor. A predictive model based on baseline cytokines was constructed in a discovery set that comprised 46 responders and 20 non-responders. In addition, an analysis of baseline cytokines of 15 responders and 12 non-responders was conducted as a validation set. The performance of the nomogram was determined using the area under the receiver operating characteristic curve (AUC) and Hosmer-Lemeshow goodness of fit test.
resultsBaseline concentrations of angiogenesis-related cytokines VEGF (P < 0.0001), placenta growth factor (PIGF) (P < 0.0001), angiopoietin-2 (Ang-2) (P < 0.0001), inflammatory factor interleukin-6 (IL-6) (P < 0.0001), IL-8 (P < 0.0001), chemokine monocyte chemoattractant protein-1 (MCP-1) (P < 0.0001), and adhesion factor intercellular adhesion molecule-1 (ICAM-1) (P < 0.001) were significantly increased compared to controls. The prediction nomogram model included five baseline cytokines: VEGF, IL-6, Ang-2, MCP-1, and ICAM-1 were constructed. The AUC for the discovery set was 0.85 (95% CI: 0.74-0.96) and for the internal validation was 0.84, indicating that the prediction model has good predictive accuracy. The Hosmer-Lemeshow goodness of fit test showed good model calibration (P = 0.295). The levels of Ang-2 (P = 0.0042), IL-6 (P < 0.0001), IL-8 (P < 0.0001), MCP-1 (P < 0.0001), and PIGF (P < 0.0001) were still significantly increased at the 6-month timepoint after multiple injections of anti-VEGF drugs for non-response group patients.
conclusionThe baseline cytokine-based model helped to assess the individual probability of response to anti-VEGF therapy. There are cytokines beyond VEGF that are involved in the pathogenesis of DME, therapeutic regimens targeting these cytokines may improve the visual acuity and reduce macular edema.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.